CAR-T Cell Therapy Market Study, 2018-2024, with Data on Yescarta and Kymriah

DUBLIN, Jan. 20, 2020 /PRNewswire/ -- The "CAR-T Cell Therapy Market Review" report has been added to ResearchAndMarkets.com's offering.

CAR-T Cell Therapy Market Review

discusses CAR-T's impressive revenue growth, which is expected to continue given the effectiveness of the therapy and the projected new users. There are positive factors for the market, though there are limits to growth. Patient volume should increase, though it is likely that the unusually large prices will not sustain over the next five years.

The report provides the following market data:

• CAR-T Market, 2018-2024 ($millions)
• CAR-T Market Share, 2019 (%)
• CAR-T Market Regional Breakout, 2019 (%)

The report discusses CAR-T therapy market trends, issues, and recent developments, including the following:

• Global Cancer Burden
• Complexity of the CARs Manufacturing Process
• Diseases Treated with CAR-T
• Study Shows Yescarta Increases Longevity
• CRS and Other Side Effects
• China CAR-T Competition
• Indian CAR-T Competition
• Off-the-Shelf CAR-T Therapies in Development
• Competing Therapy in Development

Also noted in the report are selected CAR-T therapies in development, an effort to capture current media coverage of CAR-T trials.

Key Topics Covered

1. Executive Summary

• Introduction
• CAR-T Therapy Market Trends, Issues, and Recent Developments
• CAR-T Therapy Market
• Companies in the Market

2. CAR-T Cell Therapy Market

FDA-Approved CAR-T Therapies: Yescarta and Kymriah

• Yescarta
• Kymriah
• Table 2-1: FDA-Approved CAR-T Therapies
• CAR-T Therapy Market Trends/Issues
• Global Cancer Burden
• Figure 2-1: Global Cancer Incidence Trends, 2010-2040
• Complexity of the CARs Manufacturing Process
• Diseases Treated with CAR-T

Recent Market Developments

• Study Shows Yescarta Increases Longevity
• CRS and Other Side Effects
• China CAR-T Competition
• Indian CAR-T Competition
• Off-the-Shelf CAR-T Therapies in Development
• A Competing Therapy in Development

Selected CAR-T Therapies in Development

• Table 2-2: Selected CAR-T Therapies in Development
• KTE-X19
• liso-cel
• C-CAR088
• IBI326 (Innovent)/CT103A (IASO BIO)
• bb21217
• MB-107
• ICTCAR014
• bb2121
• JNJ-682284528 (JNJ-4528)
• CT053
• MB-101 (IL-13Ra2)
• MB-108 (oncolytic virus C134)
• CYAD-01
• BAFF-R CAR-T
• MB-105 (PSCA)
• MB-102 (CD123)
• MB-103 (HER2)
• P-BCMA-101
• LCAR-B38M
• JCARH125
• MCARH171
• CYAD-101
• MB-106 (CD20)
• MB-104 (CS1)
• AMG 119
• ATA2271
• AUTO1
• AUTO3

CAR-T Market Analysis

• Figure 2-2: CAR-T Market, 2018-2024 ($millions)
• Market Share
• Figure 2-3: CAR-T Market Share, 2019 (%)
• Regional Breakout
• Figure 2-4: CAR-T Market Regional Breakout, 2019 (%)

3 Companies in the Market

• AbbVie, Inc.
• Company Summary
• Scripps Research Institute Deal
• Tyrosine Kinase Inhibitors Market
• Autolus Therapeutics plc
• Bellicum Pharmaceuticals, Inc.
• bluebird bio, Inc.
• Company Summary
• bb2121
• bb21217
• bb2121
• Bristol-Myers Squibb Company
• Company Summary
• BMS Acquires Celgene
• Monoclonal Antibodies Market
• Cancer Kinase Inhibitor Market
• CARsgen Therapeutics
• Celgene Corporation
• Company Summary
• Collaboration with Immatics Biotechnologies
• Celgene Acquires Juno, Developer of CAR-T and TCR Therapeutics, for $9 Billion
• Celgene Buys JAK2 Inhibitor Maker
• Cellectis, Inc.
• Pfizer
• Servier
• Celyad
• CYAD-01
• CYAD-101
• Gilead Sciences, Inc.
• GlaxoSmithKline
• Gracell Biotechnology
• Immune Therapeutics
• CAR-T
• Innovative Cellular Therapeutics
• ICTCAR014
• Juno Therapeutics
• Selected CAR-T Therapies in Development
• Collaboration with Editas Medicine
• Kite Pharma, Inc.
• KTE-X19
• Yescarta
• Mustang Bio
• Novartis International AG
• Company Summary
• Kymriah
• Intellia Therapeutics
• Other Company Activity
• Pfizer, Inc.
• Sorrento Therapeutics
• ZIOPHARM Oncology, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/b39hl

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets